[ad_1]
【Today, news reporter Kim Hyo-in】 Samsung Biologics and Celltrion announced plans to make Songdo the world’s largest biopharmaceutical production base by investing 2 trillion won and 500 billion won respectively in Songdo. , Incheon.
On the 18th, the government announced a strategy to promote the commercialization of the biohealth business and strengthen technological capabilities at the International Campus of Yonsei University in Songdo, Incheon.
On this day, Samsung Biologics (hereafter Samsung Bio) and Celltrion held a groundbreaking ceremony for the construction of factories 4 and 3, respectively, in Songdo International City, Incheon. On this day, the opening ceremony was held online by pressing the blast button and watching the video.
First, Samsung Bio plans to establish 4 factories with 256,000 liters, the largest in the world, based on a single factory. The plant is targeting partial production in 2022 and full operation in 2023. If Samsung Biologics, which decided to invest 1.74 trillion won for the construction of the fourth plant that began that day, secures a site for the second biocampus in In the future, the total investment will exceed 2 trillion won.
Samsung Bio explains that if the fourth plant is operated in 2023, it will ensure the capacity to produce a total of 620,000 liters of biopharmaceuticals in Songdo alone.
In 2017, when the third plant was completed, Samsung Bio already broke the records of Lonza (260,000 liters) from Switzerland and 240,000 liters of Boehringer Ingelheim (240,000 liters) of competing biopharmaceuticals (CMO). It has set the record for the world’s largest factory.
Furthermore, around 1,850 employees were recently hired and 6,400 construction workers were hired separately, so the production incentive effect is estimated to be approximately 5.7 trillion won and the job creation effect is estimated to be estimated at about 27,000.
Celltrion is also installing a third plant to build a supply and production system of various types.
Celltrion will build a third biopharmaceutical plant with a capacity of 60,000 liters taking into account the diversification of products in the future, as well as a “one-stop” large-scale research center for R&D and complex clinical trials. In this case, Celltrion will ensure a production capacity of 450,000 liters in Korea alone, and is expected to secure a total production capacity of 600,000 liters, including overseas plants in 2030.
Celltrion established 3 factories (60,000 liters) and 4 factories (200,000 liters) in addition to the first existing factory (100,000 liters) and the second factory (90,000 liters). Plan to have production capacity.
Meanwhile, around 60 bio-health research, manufacturing and service companies, including Samsung Biologics and Celltrion, currently reside in Songdo International City.
Copyright © Today Newspaper Unauthorized reproduction and redistribution prohibited
